Clinical Trials Sponsored by TauroPharm

Total 7 results

Neuropharm

Completed

Open Label Study Investigating Safety and Efficacy of NPL2009 50 mg - 150 mg on Prepulse Inhibition Tests and Continuous Performance Tasks, Adults With Fragile X Syndrome

Fragile X Syndrome

United States
Neuropharm

Terminated

Study of NPL-2003 in Adolescents With Obsessive Compulsive Disorder (OCD)

Obsessive Compulsive Disorder

United States
Palle Bekker Jeppesen
TauroPharm

Unknown

Clinical Trial Comparing Catheter Lock Solutions TaurolockTMHep 100 and Heparin 100 IE/ml.

Catheter-related Bloodstream Infection (CRBSI) Nos

Denmark
Neuropharm
Autism Speaks

Completed

Study of Fluoxetine in Autism (SOFIA)

Autistic Disorder

United States
Neuropharm
Autism Speaks

Terminated

Extended Management and Measurement of Autism (EMMA)

Autistic Disorder

United States
Aarhus University Hospital
Danish Child Cancer Foundation; TauroPharm

Completed

Taurolidine Lock Solution in the Prevention of Catheter Related Bacteremia

Neoplasms | Bacteremia

Denmark
Bayer
Biogen Netherlands B.V; Novartis Europharm Limited; Merck Europe B.V.

Not yet recruiting

An Observational Study to Learn About the Interferon-beta Exposure of Pregnant Women During the Second and Third Trimester in Finland and Sweden (INFORM)

Multiple Sclerosis (MS)

Sweden, Finland

3

Subscribe